Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma.
about
Autoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk?Cancer complicating systemic lupus erythematosus--a dichotomy emerging from a nested case-control study.Non-Hodgkin's lymphoma of the synovium discovered in total knee arthroplasty: a case reportAn unusual case of glomerulonephritis in a patient with non-Hodgkin mucosal associated lymphoid tissue (MALT) B-cell lymphoma.A genome-wide association study of marginal zone lymphoma shows association to the HLA region.Systemic lupus erythematous and malignancy risk: a meta-analysis.B-cell tolerance defects in the B6.Aec1/2 mouse model of Sjögren's syndrome.Epidemiologic overview of malignant lymphoma.Genetics of primary intraocular tumorsCancer risk in systemic lupus: an updated international multi-centre cohort study.The NFκB pathway: a therapeutic target in glioblastoma.Challenges and approaches for the development of safer immunomodulatory biologics.Preferentially immunoglobulin (IgG) subclasses production in primary Sjögren's syndrome patients.Long-term follow-up in primary Sjögren's syndrome reveals differences in clinical presentation between female and male patientsAcceleration of tumor growth due to dysfunction in M1 macrophages and enhanced angiogenesis in an animal model of autoimmune disease.The evolving concept of SLE comorbidities.Associations of Autoimmunity, Immunodeficiency, Lymphomagenesis, and Gut Microbiota in Mice with Knockins for a Pathogenic Autoantibody.Malignancies in children and young adults on etanercept: summary of cases from clinical trials and post marketing reports.Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease.Lifestyle factors, autoimmune disease and family history in prognosis of non-hodgkin lymphoma overall and subtypes.The P2X7 receptor-NLRP3 inflammasome complex predicts the development of non-Hodgkin's lymphoma in Sjogren's syndrome: a prospective, observational, single-centre study.MiR-30a increases MDSC differentiation and immunosuppressive function by targeting SOCS3 in mice with B-cell lymphoma.Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjogren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18.Reduced DICER1 Expression Bestows Rheumatoid Arthritis Synoviocytes Proinflammatory Properties and Resistance to Apoptotic Stimuli.
P2860
Q26739361-AD583C11-03C3-42A4-B308-15372C59DD57Q33937936-6594D5F8-5A65-4C41-942A-5956DB8F31F9Q34385476-7D37B9F3-D525-4B3F-967F-8EBE74D31605Q34856837-4D316B24-4277-476D-AD27-C91E1D472223Q34881099-7C86ABDA-C059-4CEC-BB7E-295006D964A7Q35464796-D1AB35DD-2C88-41BE-A0B0-2BB5C4820A9CQ35957443-51C98497-BB49-4BAB-ACA9-EF73A1DD3C0FQ36074055-E4A398A5-1E90-436E-B079-80EEF2ADF6F1Q36216850-D08D0185-64C8-4388-854E-5C956DA759D8Q36823763-8F41BF8A-8F52-44A4-A1CC-B2E0FE00CA03Q37928304-80E3B17F-B603-49D2-A36D-49832C73BB6CQ38093772-EDBE68CE-C658-45F5-93EB-D235F40F0075Q38407400-EA5B887B-6A1F-4A43-8843-ED601710F97FQ38633508-88D26EED-D37F-457A-810C-7787889C3A05Q38799583-91E0F117-AC14-4D27-8277-5D6E91E8FB70Q39283399-347E1C6D-3168-44D8-BA17-31B450089D24Q40114844-5ADDF639-10EF-4F97-8BBD-2EB9C49C7E0CQ42029571-CB518FFE-D98E-4BB8-BFC0-F69696B07248Q44455716-8684E7EB-FBAC-4446-BEBA-8D0764A4AEF6Q46654494-2EE8414B-7533-4E8C-AB8A-FAF8E813B856Q48146038-75E1749C-A781-4D42-A936-6FBA6ABD110DQ50948891-4404C69E-08B3-4F6A-AF84-E5039BE08ACDQ53542274-5EFBAECF-BF49-4050-9B07-FD05485E466CQ53797117-0244D6EB-3FEB-4814-8733-C0445AA82CDB
P2860
Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma.
@en
Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma.
@nl
type
label
Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma.
@en
Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma.
@nl
prefLabel
Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma.
@en
Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma.
@nl
P2860
P356
P1476
Susceptibility of patients with rheumatic diseases to B-cell non-Hodgkin lymphoma
@en
P2093
Catarina Dias
P2860
P2888
P304
P356
10.1038/NRRHEUM.2011.62
P407
P577
2011-06-01T00:00:00Z